Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or ...
January 08 2019 - 9:16AM
Edgar (US Regulatory)
|
UNITED STATES
|
|
SECURITIES AND EXCHANGE COMMISSION
|
|
Washington, D.C. 20549
|
|
FORM 25
|
|
|
NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b)
OF THE SECURITIES EXCHANGE ACT OF 1934.
|
|
|
|
|
Commission File Number
001-34708
|
|
|
Issuer:
|
Biostar Pharmaceuticals, Inc.
|
|
Exchange:
|
The Nasdaq Stock Market LLC
|
|
(Exact name of Issuer as specified in its charter, and name of
Exchange where security is listed and/or registered)
|
|
|
|
Address:
|
No. 588 Shiji Avenue
Xianyang City Shaanxi Province,
CHINA
712046
|
|
Telephone number:
|
860 2933686638
|
|
(Address, including zip code, and telephone number, including area code, of Issuer's
principal executive offices)
|
|
|
|
Common Stock
|
|
(Description of class of securities)
|
|
|
|
Please place an X in the box to designate the rule provision relied upon to strike
the class of securities from listing and registration:
|
|
o
17 CFR 240.12d2-2(a)(1)
|
|
o
17 CFR 240.12d2-2(a)(2)
|
|
o
17 CFR 240.12d2-2(a)(3)
|
|
o
17 CFR 240.12d2-2(a)(4)
|
|
x
Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange.
1
|
|
o
Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.
|
|
|
|
Pursuant to the requirements for the Securities Exchange Act of 1934,
The Nasdaq Stock Market LLC
certifies that it has reasonable grounds to believe that it
meets all of the requirements for filing the Form 25 and has caused this notification to be
signed on its behalf by the undersigned duly authorized person.
|
|
|
|
2019-01-08
|
By
|
Amy Horton
|
|
Hearings Advisor
|
|
Date
|
|
Name
|
|
Title
|
|
|
|
1
|
Form 25 and attached Notice will be considered compliance with the provisions of
17 CFR 240.19d-1 as applicable.
See
General Instructions.
|
Biostar Pharmaceuticals (CE) (USOTC:BSPM)
Historical Stock Chart
From Oct 2024 to Nov 2024
Biostar Pharmaceuticals (CE) (USOTC:BSPM)
Historical Stock Chart
From Nov 2023 to Nov 2024
Real-Time news about Biostar Pharmaceuticals Inc (CE) (OTCMarkets): 0 recent articles
More Biostar Pharmaceuticals, Inc. News Articles